BridgeBio Oncology Therapeutics, Inc. (BBOT) — Cash Flow-to-Debt Ratio
BridgeBio Oncology Therapeutics, Inc. (BBOT) has a Cash Flow-to-Debt Ratio of -1.13x as of December 2025, meaning its operating cash flow of $-42.23 Million could theoretically repay -1% of its total liabilities ($37.28 Million) in one year. See BridgeBio Oncology Therapeutics, Inc. current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
BridgeBio Oncology Therapeutics, Inc. Cash Flow-to-Debt Ratio (2023–2025)
Historical debt coverage capacity for BridgeBio Oncology Therapeutics, Inc. across 3 annual periods. Also explore BBOT net assets growth trend to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for BridgeBio Oncology Therapeutics, Inc. (2023–2025)
Year-by-year debt coverage analysis for BridgeBio Oncology Therapeutics, Inc.. For market capitalisation and broader financial context, see BridgeBio Oncology Therapeutics, Inc. market capitalisation.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.05x | $-113.89 Million | $37.28 Million | ▼ -2182.6% |
| 2024 | -0.13x | $-763.82K | $5.71 Million | ▲ +99.9% |
| 2023 | -131.36x | $-52.08 Million | $396.46K | — |